Sanofi winds $40m into UK gene therapy firm GyroscopeFrench drugmaker Sanofi has made a $40 million investment in Gyroscope Therapeutics, with another $20 million potentially on Share XSanofi winds $40m into UK gene therapy firm Gyroscopehttps://pharmaphorum.com/news/sanofi-winds-40m-into-uk-gene-therapy-firm-gyroscope/
AbbVie claims first FDA okay for presbyopia drug therapyThe FDA has approved the first and so far only pharmacological treatment for presbyopia, a sight condition that Share XAbbVie claims first FDA okay for presbyopia drug therapyhttps://pharmaphorum.com/news/abbvie-claims-first-fda-okay-for-presbyopia-drug-therapy/
Luminopia scores FDA approval for TV-based amblyopia therapyHard on the heels of some impressive clinical trial results, Luminopia has won FDA approval for its digital Share XLuminopia scores FDA approval for TV-based amblyopia therapyhttps://pharmaphorum.com/news/luminopia-scores-fda-approval-for-tv-based-amblyopia-therapy/
FDA clears Roche’s Susvimo implant for eye disease wet AMDRoche’s Genentech unit has won FDA approval for Susvimo, an implant for eyesight-robbing disease wet age-related macular degeneration Share XFDA clears Roche’s Susvimo implant for eye disease wet AMDhttps://pharmaphorum.com/news/fda-clears-roches-susvimo-implant-for-eye-disease-wet-amd/
FDA OKs first biosimilar of Roche’s blockbuster AMD drug LucentisSamsung Bioepis and Biogen have claimed the first FDA approval for a biosimilar version of Roche and Novartis’ Share XFDA OKs first biosimilar of Roche’s blockbuster AMD drug Lucentishttps://pharmaphorum.com/news/fda-oks-first-biosimilar-of-roches-blockbuster-amd-drug-lucentis/
Luminopia’s digital therapy for lazy eye aces clinical trialA digital therapeutic (DTx) for amblyopia – sometimes known as lazy eye – has been shown to improve Share XLuminopia’s digital therapy for lazy eye aces clinical trialhttps://pharmaphorum.com/news/luminopias-digital-therapy-for-lazy-eye-aces-clinical-trial/
AbbVie spies potential in Regenxbio eye disease gene therapyAbbVie has expanded its ophthalmology pipeline via a licensing deal with Regenxbio, paying $370 million upfront to get Share XAbbVie spies potential in Regenxbio eye disease gene therapyhttps://pharmaphorum.com/news/abbvie-spies-potential-in-regenxbio-eye-disease-gene-therapy/
Apellis reports mixed data with eye drug, but plans to file anywayApellis Pharma has reported mixed results with its lead drug pegcetacoplan in geographic atrophy (GA) – a major Share XApellis reports mixed data with eye drug, but plans to file anywayhttps://pharmaphorum.com/news/apellis-reports-mixed-data-with-eye-drug-but-plans-to-file-anyway/
Europe has its first Lucentis biosimilar, Samsung Bioepis’ ByoovizNovartis and Roche’s big-selling eye drug Lucentis has its first biosimilar competitor in Europe, after the European Commission Share XEurope has its first Lucentis biosimilar, Samsung Bioepis’ Byoovizhttps://pharmaphorum.com/news/europe-has-its-first-lucentis-biosimilar-samsung-bioepis-byooviz/
